Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.

Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, Gómez-Reino JJ; BIOBADASER and EMECAR Groups.

Ann Rheum Dis. 2007 Jul;66(7):880-5. Epub 2007 Feb 26.

2.

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, Carreño L, Figueroa M; BIOBADASER Group.

Arthritis Rheum. 2005 Jun;52(6):1766-72.

3.

Cancer in patients with rheumatic diseases exposed to TNF antagonists.

Carmona L, Abasolo L, Descalzo MA, Pérez-Zafrilla B, Sellas A, de Abajo F, Gomez-Reino JJ; BIOBADASER Study Group; EMECAR Study Group.

Semin Arthritis Rheum. 2011 Aug;41(1):71-80. doi: 10.1016/j.semarthrit.2010.08.005. Epub 2010 Nov 18.

PMID:
21093020
4.

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

Jacobsson LT, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P.

J Rheumatol. 2005 Jul;32(7):1213-8.

PMID:
15996054
5.

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N.

Ann Rheum Dis. 2005 Oct;64(10):1414-20. Epub 2005 Apr 20.

6.

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group.

Arthritis Rheum. 2007 Jun 15;57(5):756-61.

7.

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.

Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P.

Ann Rheum Dis. 2007 May;66(5):670-5. Epub 2006 Dec 11.

8.

Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.

Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M; Real Study Group.

Arthritis Care Res (Hoboken). 2012 Aug;64(8):1125-34. doi: 10.1002/acr.21666.

9.

Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.

Thyagarajan V, Norman H, Alexander KA, Napalkov P, Enger C.

Semin Arthritis Rheum. 2012 Dec;42(3):223-33. doi: 10.1016/j.semarthrit.2012.05.004. Epub 2012 Jun 28.

PMID:
22748510
10.

Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.

Al-Aly Z, Pan H, Zeringue A, Xian H, McDonald JR, El-Achkar TM, Eisen S.

Transl Res. 2011 Jan;157(1):10-8. doi: 10.1016/j.trsl.2010.09.005. Epub 2010 Oct 21.

PMID:
21146146
11.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
12.

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

Carmona L, Gómez-Reino JJ; BIOBADASER Group.

Arthritis Res Ther. 2006;8(3):R72. Epub 2006 Apr 18.

13.

Long-term mortality rate in rheumatoid arthritis patients with disease onset in the 1980s.

Kapetanovic MC, Lindqvist E, Geborek P, Saxne T, Eberhard K.

Scand J Rheumatol. 2011 Nov;40(6):433-8. doi: 10.3109/03009742.2011.573503. Epub 2011 May 30.

PMID:
21619489
14.

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.

Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven RF, Klareskog L.

Ann Rheum Dis. 2007 Oct;66(10):1339-44. Epub 2007 Jan 29. Erratum in: Ann Rheum Dis. 2007 Nov;66(11):1548.

15.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

16.

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.

Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N.

Arthritis Rheum. 2005 Jul;52(7):1986-92.

17.

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.

Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Ann Rheum Dis. 2005 Oct;64(10):1421-6. Epub 2005 Apr 13.

18.

Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.

Peña-Sagredo JL, Fariñas MC, Perez-Zafrilla B, Cruz-Valenciano A, Crespo M, Joven-Ibañez B, Riera E, Manero-Ruiz FJ, Chalmeta I, Hernández MV, Rodríguez-Gómez M, Maíz O, López R, Cobo T, Pita J, Carmona L, Gonzalez-Gay MA; BIOBADASER and EMECAR Groups.

Clin Exp Rheumatol. 2009 Nov-Dec;27(6):920-5.

PMID:
20149306
19.

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, O'Fallon WM, Gabriel SE.

Ann Rheum Dis. 2008 Jan;67(1):64-9. Epub 2007 May 21.

PMID:
17517756
20.

Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.

Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo MÁ, Carmona L; BIOBADASER 2.0 Study Group.

Ann Rheum Dis. 2012 Mar;71(3):382-5. doi: 10.1136/annrheumdis-2011-200302. Epub 2011 Oct 13.

PMID:
21998116

Supplemental Content

Support Center